Skip to content
ClinCalc Pro
Menu
Opioid Analgesic — Transdermal Patch

Fentanyl Transdermal Patch (Elderly Chronic Pain)

Brand names: Durogesic DTrans, Matrifen, Mezolar

Transdermal fentanyl is a potent opioid analgesic delivering a strong opioid through the skin for stable, persistent chronic pain, with particular caution in elderly patients.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Fentanyl is a synthetic mu-opioid receptor agonist that produces analgesia by acting on opioid receptors in the central nervous system.

Prescribing in practice

  • Transdermal fentanyl must not be used in opioid-naive patients because its potency carries a high risk of fatal respiratory depression, a risk increased in the elderly.
  • It is unsuitable for acute or rapidly changing pain owing to its slow onset and prolonged offset, and a depot persists in the skin after patch removal.
  • Fever, external heat sources and damaged skin can accelerate absorption and precipitate overdose.

Monitoring

Monitor for sedation, respiratory depression, confusion, constipation and adequacy of analgesia, especially during initiation and dose change in older patients.

Counselling the patient

  • Do not expose the patch or the area to direct heat such as hot baths, heat pads or electric blankets.
  • Fold used patches closed and dispose of them safely away from children, as they still contain medicine.
  • Report excessive drowsiness or slow or shallow breathing urgently.

Evidence & guidelines

Transdermal fentanyl is an established option for stable chronic pain, with safe use in the elderly guided by MHRA and UK prescribing references.

Reference: SIGN 106 (Control of Pain in Adults with Cancer); NICE NG215 (Chronic Pain in Adults); MHRA SPC Durogesic; MHRA Drug Safety Update 2020 (opioid + CNS depressants); Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.